Clinical Scorecard: The Role of Platelets in the Advancement of Fatty Liver Disease Linked to Metabolic Dysfunction-Associated Steatohepatitis: A Review of Pathophysiological Mechanisms

At a Glance

Key Highlights

• Platelets are significantly involved in the pathogenesis of MASH beyond hemostasis.
• Increased platelet activation correlates with disease severity and progression.
• Platelet-related markers may serve as non-invasive indicators for monitoring MASH.
• Targeting platelet activity shows potential therapeutic benefits in MASH management.
• Advanced MASH is associated with a hypercoagulable state and altered platelet indices.

Guideline-Based Recommendations

Diagnosis

• Monitor platelet activation markers as part of MASH assessment.
• Evaluate liver function tests and imaging to assess disease severity.

Management

• Consider antiplatelet agents in combination with antifibrotic therapies.
• Implement lifestyle modifications targeting metabolic dysfunction.

Monitoring & Follow-up

• Regularly assess platelet indices and liver function parameters.
• Utilize non-invasive markers for tracking disease progression.

Risks

• Increased risk of cirrhosis and hepatocellular carcinoma if MASH is unmanaged.
• Potential complications from hypercoagulable state in advanced MASH.

Patient & Prescribing Data

Individuals with metabolic dysfunction and MASH.

Combination therapies targeting both platelet activity and metabolic dysregulation may enhance treatment efficacy.

Clinical Best Practices

• Integrate platelet monitoring into routine clinical assessments for MASH.
• Explore combination therapies to address multifactorial aspects of MASH.

References

• Pathophysiological mechanisms of MASH